Glycorex Transplantation AB (GTAB B): Interim report January - September 2022
“After a strong second quarter, the third quarter of 2022 continued with good sales growth in most of the company’s markets. The development is in line with our long-term ambitions to create sustainable sales growth.” July – September 2022 Net sales: SEK 8.8 million (8.6)Operating income: SEK -0.8 million (-0.4)Net income for the period: SEK -0.8 million (-0.5)Earnings per share: SEK -0.01 (-0.01) Events in the third quarter · Continued post COVID-19-market rebound with an increased order intake from most of the company ́s markets. · First order for Glycosorb® ABO